Clinical Trial Update: An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

View source ↗

Summary

This update notes that the expanded access treatment protocol for Zanidatamab (ZW25) in patients with HER2-positive advanced biliary tract cancer is no longer a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• ZW25 (Zanidatamab) (Zanidatamab)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: HER2-Positive Advanced Biliary Tract Cancer | Status: NO_LONGER_AVAILABLE